Locteron™ is Octoplus’ controlled release formulation of alfa interferon for the treatment of chronic hepatitis C. On 27th April, the dutch drug delivery and development company (Octoplus) announced the results of the completed Phase 1 study on Locteron™.
Phase I results show that a single dose of Locteron delivered to healthy volunteers is safe and results supported that Locteron could be effectively dosed once every two weeks, which is a substantial improvement over the current pegylated interferons that require dosing every week.
These results have been presented at the 41st Annual Meeting of the European Association for the Study of Liver Disease (EASL) meeting in Vienna, Austria.
Locteron™ has been designed to be a best-in-class therapeutic for patients with chronic hepatitis C which has the potential to induce less side effects and to increase therapeutic efficacy and patient compliance compared with current therapies; will enter into Phase II studies in the second half of 2006.
Source: Octoplus News
Comment Preview